Oklo Inc. Is Worth $6 Billion but Can't Price Its Own Reactor

NEW YORK, April 4 —

Oklo Inc. (OKLO) expects to spend as much as $550 million in 2026. Revenue from its reactor business: zero. The company's CFO has told investors the cost of its first commercial Aurora reactor won't be known until later this year. That means every analyst model behind a $91 price target uses a placeholder where the most important input should be.

What the Street Believes

Wall Street is betting on Oklo as a first-mover in advanced fission. The consensus target of $91.03—nearly double the current $48.13 share price—assumes that DOE backing, an NRC licensing pathway, and rising hyperscaler demand for clean baseload power give Oklo a clear path to commercial deployment between 2028 and 2030. Analysts treat the stock as a call option on that deployment curve: if Aurora reactors get built at reasonable cost and on schedule, the return is enormous. The average target says the market should roughly double its bet from here.

Here's the problem no one is modeling around. That option-value framework requires at least a rough estimate of what one reactor costs to build. Oklo's own finance team cannot provide that number. You cannot value an option when the strike price is a blank cell in the spreadsheet. Every revenue projection, every margin assumption, every DCF that lands at $91 is structurally unfalsifiable—because the single most important variable, the unit economics of an Aurora reactor, is not yet known to the people building it.

What the Data Actually Shows

Start with the earnings trajectory. Four quarters ago, Oklo posted a loss of $0.07 per share against estimates of $0.11—a 36% beat. Pre-revenue companies beating on the upside of their burn rate is a good signal. It suggests disciplined spending. Then something changed. Three quarters ago, the loss came in at $0.18 versus an $0.11 estimate, a 64% miss. The most recent quarter: a $0.20 loss versus $0.12 expected, another 64% miss. The trend is not ambiguous. Oklo went from spending less than expected to spending dramatically more. The misses are widening, not narrowing.

"I think we'll have more information to share around what the cost of that first asset looks like later this year."

That's the CFO, on the record, telling investors that Aurora's unit cost—the number Oklo's entire valuation revolves around—won't have real figures attached until the back half of 2026. Pair this with the guided $350-450 million capex range for the year. Oklo is preparing to pour hundreds of millions into construction-phase spending before it knows what a finished reactor costs. This is a homebuilder breaking ground before the architect finishes the blueprints. Sometimes that works. Usually it means change orders.

Then there's the timeline. Oklo's Aurora deployment at Idaho National Laboratory was previously targeted for late 2027. In Q4 remarks, that shifted to 2028. Management called it "balancing speed-to-market against capital optimization"—a polished way of saying it's taking longer and costing more than initially signaled. Citi flagged the slip. The market shrugged. But a one-year delay in a pre-revenue company compounds in ways that don't show up in a consensus model built on terminal value.

Why This Changes Everything

Oklo reported $1.4 billion in cash, which sounds like plenty of runway. Run the math on the 2026 guidance. If the company hits the high end—$100 million in operating costs plus $450 million in capex—that's $550 million out the door in a single year. That consumes roughly 39% of the entire cash pile before a single reactor generates a dollar of revenue. And 2027 won't be cheaper. If Aurora's first deployment is now a 2028 event, Oklo needs to fund at least two more years of heavy spending before any commercial operation begins.

Free cash flow is already ugly: negative $80 million on a trailing twelve-month basis, and that's before the capex ramp kicks in. At the current forward P/E of negative 57x, the market is not just tolerating losses—it's pricing in a future where these losses become large profits. For that to happen, two things need to go right at once: Aurora needs to cost a buildable amount per unit, and Oklo needs to deploy enough of them fast enough to justify a multi-billion-dollar enterprise value. The CFO just told you they can't yet confirm the first condition.

The catalyst is straightforward. When Oklo discloses that first-reactor cost estimate later this year, every model reprices overnight. If the number comes in higher than the placeholder assumptions baked into $91 targets, the implied deployment count per dollar of capital drops. The stock then has a valuation problem it can't talk its way around.

The Bull Case

The bull case is real and worth respecting. Nuclear energy demand from hyperscalers is not speculative—it's contractual. Microsoft, Google, and Amazon have all made public commitments to nuclear procurement. Oklo's DOE relationship and its position in the Aurora risk-reduction program at INL give it a head start that pure-play competitors cannot easily replicate. The Blykalla partnership broadens Oklo's fast-reactor ecosystem and may accelerate technology validation. And $1.4 billion in cash, even after a heavy 2026, likely gets the company to first deployment without another dilutive raise.

Those are legitimate strengths. But they are strategic advantages, not financial ones. Strategic advantages have to convert into unit economics before they create shareholder value. Right now, the conversion rate is zero. And the timeline for learning whether it will ever turn positive just got pushed back a year.

The Bottom Line

Oklo is asking investors to value a product whose cost its own management cannot yet estimate. The $91 consensus target represents an 89% premium built entirely on models where the most critical input—what it costs to build an Aurora reactor—is a guess. The earnings trend is deteriorating, from a 36% beat to consecutive 64% misses. The deployment timeline has slipped by roughly a year. The 2026 burn rate could eat nearly 40% of remaining cash. None of this means Oklo fails. It means the stock, at $48, is priced for a level of certainty that does not exist. For investors who want the full financial picture, run the free Oklo Inc. deep-dive before the cost disclosure reshapes the math. The moment to get interested is when Oklo can answer the question it's been dodging: what does one reactor actually cost?

Basis Report does not hold positions in securities discussed. This is not investment advice.

Frequently Asked Questions

What is the cost of Oklo's Aurora reactor?

As of April 2026, Oklo's CFO has stated the company will have "more information to share around what the cost of that first asset looks like later this year." No specific cost per reactor has been disclosed publicly.

How much cash does Oklo have and how long is its runway?

Oklo reported $1.4 billion in cash. The company guides to $80-100 million in operating expenses and $350-450 million in capital expenditures for 2026, meaning up to $550 million in total outflows this year. At the high end, that would consume roughly 39% of cash reserves in a single year.

When will Oklo's first Aurora reactor be operational?

The Aurora deployment at Idaho National Laboratory was initially targeted for late 2027 but shifted to 2028 in Q4 remarks. Management characterized the change as balancing speed-to-market with capital optimization.

Why is Oklo's stock price so far below the analyst consensus target?

Oklo trades at $48.13 against a $91 consensus target, an 89% gap. The disconnect reflects the market pricing in more uncertainty than sell-side models, which rely on deployment and cost assumptions that management itself has not yet confirmed.

Is Oklo profitable?

No. Oklo is pre-revenue from its core reactor business and posted a loss of $0.20 per share in its most recent quarter, missing estimates by 64%. Trailing twelve-month free cash flow is negative $80 million, and losses are expected to widen as capex ramps through 2026.